What does this research mean for the field?

Despite recent improvements in survival, long-term outcomes in lung transplantation remain limited by chronic allograft dysfunction and infections, requiring continued advancements across the transplant continuum to extend graft survival and improve patient quality of life. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Synthesize contemporary evidence and evolving paradigms across the entire lung transplantation continuum, from donor selection and surgical execution to long-term allograft maintenance.

September 8, 2026European Respiratory Journal

From donor to durable graft: modern paradigms in lung transplantation

View Full Paper

Ask AI

Bookmark

Authors

YGYasufumi GodaBrigham and Women's Hospital RFRamiro FernandezBaylor College of Medicine GLGloria W. LiBaylor College of Medicine

Discussion

Member takes

Overview

Comprehensive review demonstrates evolving strategies across the lung transplant continuum in end-stage respiratory disease, highlighting opportunities to improve graft survival.

Key Points

Synthesize contemporary evidence and evolving paradigms across the entire lung transplantation continuum, from donor selection and surgical execution to long-term allograft maintenance.
Reviewed contemporary donor expansion paradigms, including donation after circulatory death, ex vivo lung perfusion, and living-donor lobar transplantation.
Assessed recent candidate allocation frameworks, frailty scoring, operative management, and mechanical circulatory support strategies.
Synthesized protocols for immunosuppressive maintenance, infection prophylaxis, diagnostic monitoring, and investigational frontiers like cell-free DNA and xenotransplantation.
Expanded donor criteria and ex vivo lung perfusion protocols increase donor organ utilization while limiting primary graft dysfunction and perioperative morbidity.
Chronic lung allograft dysfunction and infectious complications remain the dominant contributors to lower long-term survival compared with other solid organ transplants.
Emerging innovations, including donor-derived cell-free DNA surveillance and targeted cell therapies, show promise for early rejection detection and reduced immunosuppression toxicity.

Cite This Study

Goda et al. (2026) studied this question.

synapsesocial.com/papers/6aa0091858e84d0ff5b47b73 https://doi.org/10.1183/13993003.00165-2026

View Full Paper

Ask AI

Bookmark

September 8, 2026European Respiratory Journal

From donor to durable graft: modern paradigms in lung transplantation

View Full Paper

Ask AI

Bookmark

Authors

YGYasufumi GodaBrigham and Women's Hospital RFRamiro FernandezBaylor College of Medicine GLGloria W. LiBaylor College of Medicine

Discussion

Member takes

Overview

Comprehensive review demonstrates evolving strategies across the lung transplant continuum in end-stage respiratory disease, highlighting opportunities to improve graft survival.

Key Points

Synthesize contemporary evidence and evolving paradigms across the entire lung transplantation continuum, from donor selection and surgical execution to long-term allograft maintenance.
Reviewed contemporary donor expansion paradigms, including donation after circulatory death, ex vivo lung perfusion, and living-donor lobar transplantation.
Assessed recent candidate allocation frameworks, frailty scoring, operative management, and mechanical circulatory support strategies.
Synthesized protocols for immunosuppressive maintenance, infection prophylaxis, diagnostic monitoring, and investigational frontiers like cell-free DNA and xenotransplantation.
Expanded donor criteria and ex vivo lung perfusion protocols increase donor organ utilization while limiting primary graft dysfunction and perioperative morbidity.
Chronic lung allograft dysfunction and infectious complications remain the dominant contributors to lower long-term survival compared with other solid organ transplants.
Emerging innovations, including donor-derived cell-free DNA surveillance and targeted cell therapies, show promise for early rejection detection and reduced immunosuppression toxicity.

Cite This Study

Goda et al. (2026) studied this question.

synapsesocial.com/papers/6aa0091858e84d0ff5b47b73 https://doi.org/10.1183/13993003.00165-2026

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark